Using doxorubicin and siRNA-loaded heptapeptide-conjugated nanoparticles to enhance chemosensitization in epidermal growth factor receptor high-expressed breast cancer cells

Journal of Drug Targeting

Volumn 21, Issue 8, 2013, Pages 776-786

  Liu, Chia Wen ^a,b   Lin, Wen Jen ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE   (Taiwan)

Author keywords

Cancer targeting; Nanoparticles; Peptide; PLGA PEG; SiRNA

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; COPOLYMER; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; HEPTAPEPTIDE; NANOPARTICLE; POLY(LACTIDE CO GLYCOLIDE) POL(ETHYLENE GLYCOL) COPOLYMER; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL STRAIN HEPG2; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG TARGETING; ENDOCYTOSIS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PARTICLE SIZE; PH; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURFACE PROPERTY;

BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; FEMALE; HEP G2 CELLS; HUMANS; NANOPARTICLES; PARTICLE SIZE; PEPTIDES; POLYETHYLENE GLYCOLS; POLYGLACTIN 910; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, SMALL INTERFERING;

EID: 84883235338     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2013.811511     Document Type: Article

References (57)

1. Weiguang Y, Dalin L, Lidan X, et al. Association of OX40L Polymorphisms with sporadic breast cancer in northeast Chinese Han population. PLoS One 2012;7:e41277 (1-6).
2. Kamigaki Y, Kawakami K. Risk of second cancer after initial treatment of breast cancer: an Osaka cancer registry database study. Oncol Lett 2011;2: 963-73.
3. Balz LM, Bartkowiak K, Andreas A, et al. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-gamma1 signalling in breast cancer cell migration and dissemination. J Pathol 2012;227: 234-44.
4. Khoee S, Rahmatolahzadeh R. Synthesis and characterization of pH-responsive and folated nanoparticles based on self-assembled brush-like PLGA/PEG/AEMA copolymer with targeted cancer therapy properties: a comprehensive kinetic study. Eur J Med Chem 2012;50: 416-27.
5. Tian XH, Wei F, Wang TX, et al. In vitro and in vivo studies on gelatin-siloxane nanoparticles conjugated with SynB peptide to increase drug delivery to the brain. Int J Nanomed 2012;7: 1031-41.
6. Hillaireau H, Couvreur P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol Life Sci 2012;66: 2873-96.
7. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem 2010;21: 797-802.
8. Kamaly N, Xiao Z, Valencia PM, et al. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev 2012;41: 2971-3010.
9. Choi SK, Verma M, Silpe J, et al. A photochemical approach for controlled drug release in targeted drug delivery. Bioorg Med Chem 2012;20: 1281-90.
10. Shroff K, Kokkoli E. PEGylated liposomal doxorubicin targeted to alpha5beta1-expressing MDA-MB-231 breast cancer cells. Langmuir 2012;28: 4729-36.
11. Reinehr R, Haussinger D. CD95 death receptor and epidermal growth factor receptor (EGFR) in liver cell apoptosis and regeneration. Arch Biochem Biophys 2012;518: 2-7.
12. Milella M, Nuzzo C, Bria E, et al. EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/ clinically selected patients pretreated with chemotherapy. J Thorac Oncol 2012;7: 672-80.
13. Lamy PJ, Jacot W. Worldwide variations in EGFR somatic mutations: a challenge for personalized medicine. Diagn Pathol 2012;7: 13-14.
14. Zajchowski DA, Karlan BY, Shawver LK. Treatment-related protein biomarker expression differs between primary and recurrent ovarian carcinomas. Mol Cancer Ther 2012;11: 492-502.
15. Eccles SA. The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology. Int J Dev Biol 2011;55: 685-96.
16. Stella GM, Luisetti M, Inghilleri S, et al. Targeting EGFR in nonsmall- cell lung cancer: lessons, experiences, strategies. Respir Med 2012;106: 173-83.
17. Vlahovic G, Meadows KL, Uronis HE, et al. A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors. Cancer Chemother Pharmacol 2012;70: 95-102.
18. Shen Y, Yang J, Xu Z, et al. Phosphatase and tensin homolog expression related to cetuximab effects in colorectal cancer patients: a meta-analysis. World J Gastroenterol 2012;18: 2712-18.
19. Altintas I, Kok RJ, Schiffelers RM. Targeting epidermal growth factor receptor in tumors: from conventional monoclonal antibodies via heavy chain-only antibodies to nanobodies. Eur J Pharm Sci 2012;45: 399-407.
20. Saxena R, Dwivedi A. ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective. Med Res Rev 2012;32: 166-215.
21. Rahman MA, Amin AR, Wang X, et al. Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth. J Control Rel 2012;159: 384-92.
22. Kundu AK, Chandra PK, Hazari S, et al. Development and optimization of nanosomal formulations for siRNA delivery to the liver. Eur J Pharm Biopharm 2012;80: 257-67.
23. Kneidinger D, Ibrisimovic M, Lion T, Klein R. Inhibition of adenovirus multiplication by short interfering RNAs directly or indirectly targeting the viral DNA replication machinery. Antiviral Res 2012;94: 195-207.
24. Burnett JC, Rossi JJ. RNA-based therapeutics: current progress and future prospects. Chem Biol 2012;19: 60-71.
25. Zhang C, Montgomery TA, Fischer SE, et al. The Caenorhabditis elegans RDE-10/RDE-11 complex regulates RNAi by promoting secondary siRNA amplification. Curr Biol 2012;22: 881-90.
26. Shojaei F. Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett 2012;320: 130-7.
27. Zhao S, Ma D, Dai H, et al. Biologically inhibitory effects of VEGF siRNA on endometrial carcinoma cells. Arch Gynecol Obstet 2011; 284: 1533-41.
28. Burnett JC, Rossi JJ, Tiemann K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J 2011;6: 1130-46.
29. Shen Y. Advances in the development of siRNA-based therapeutics for cancer. Drugs 2008;11: 572-8.
30. Giacomini KM, Huang SM, Tweedie DJ, et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010;9: 215-36.
31. Astier A, Doat B, Ferrer MJ, et al. Enhancement of adriamycin antitumor activity by its binding with an intracellular sustainedrelease form, polymethacrylate nanospheres, in U-937 cells. Cancer Res 1988;48: 1835-41.
32. Liu CW, Lin WJ. Polymeric nanoparticles conjugate a novel heptapeptide as an active targeting ligand for doxorubicin. Inter J Nanomed 2012;7: 4749-67.
33. Tahara K, Sakai T, Yamamoto H, et al. Establishing chitosan coated PLGA nanosphere platform loaded with wide variety of nucleic acid by complexation with cationic compound for gene delivery. Int J Pharm 2008;354: 210-16.
34. Song S, Liu D, Peng J, et al. Novel peptide ligand directs liposomes toward EGF-R high-expressing cancer cells in vitro and in vivo. FASEB J 2009;23: 1396-404.
35. Tseng CL, Wang TW, Dong GC, et al. Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting. Biomaterials 2007;28: 3996-4005.
36. Chittasupho C, Xie SX, Baoum A, et al. ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells. Eur J Pharm Sci 2009;37: 141-50.
37. Mendoza-Espinoza MC, LaJA. Cytotoxic evaluation of fluvastatin and rosuvastatin and effect of fluvastatin in the hela cell cycle. African J Pharm Pharmacol 2011;5: 322-6.
38. Couvreur P, Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm Res 2006;23: 1417-50. (Pubitemid 43993807)
39. Itabashi H, Maesawa C, Oikawa H, et al. Angiotensin II and epidermal growth factor receptor cross-talk mediated by a disintegrin and metalloprotease accelerates tumor cell proliferation of hepatocellular carcinoma cell lines. Hepatol Res 2008;38: 601-13. (Pubitemid 351622286)
40. Shirako E, Hirayama N, Tsukada Y, et al. Up-regulation of p21CIP1 expression mediated by ERK-dependent and -independent pathways contributes to hepatocyte growth factor-induced inhibition of HepG2 hepatoma cell proliferation. J Cell Biochem 2008;104: 176-88.
41. Kolonin MG, Bover L, Sun J, et al. Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries. Cancer Res 2006;66: 34-40. (Pubitemid 43166005)
42. Longva KE, Pedersen NM, Haslekas C, et al. Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. Int J Cancer 2005;116: 359-67. (Pubitemid 40993331)
43. He X, Ota T, Liu P, et al. Downregulation of HtrA1 promotes resistance to anoikis and peritoneal dissemination of ovarian cancer cells. Cancer Res 2010;70: 3109-18.
44. Turner JG, Dawson J, Sullivan DM. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 2012;83: 1021-32.
45. Li YT, Chua MJ, Kunnath AP, Chowdhury EH. Reversing multidrug resistance in breast cancer cells by silencing ABC transporter genes with nanoparticle-facilitated delivery of target siRNAs. Int J Nanomed 2012;7: 2473-81.
46. Huang M, Ma Z, Khor E, Lim LY. Uptake of FITC-chitosan nanoparticles by A549 cells. Pharm Res 2002;19: 1488-94. (Pubitemid 35266553)
47. Bareford LM, Swaan PW. Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev 2007;59: 748-58. (Pubitemid 47320813)
48. Tahara K, Yamamoto H, Hirashima N, Kawashima Y. Chitosanmodified poly(D,L-lactide-co-glycolide) nanospheres for improving siRNA delivery and gene-silencing effects. Eur J Pharm Biopharm 2010;74: 421-6.
49. Li Z, Zhao R, Wu X, et al. Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J 2005;19: 1978-85. (Pubitemid 41759743)
50. Song S, Liu D, Peng J, et al. Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo. Int J Pharma 2008;363: 155-61.
51. Gillies ER, Fréchet JM. pH-responsive copolymer assemblies for controlled release of doxorubicin. Bioconjug Chem 2005;16: 361-8. (Pubitemid 40388212)
52. Kim J, Lee YJ, Shin DS, et al. Cosmomycin C inhibits signal transducer and activator of transcription 3 (STAT3) pathways in MDA-MB-468 breast cancer cell. Bioorg Med Chem 2011;19: 7582-9.
53. Mesri M, Morales-Ruiz M, Ackermann EJ, et al. Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am J Pathol 2001;158: 1757-65. (Pubitemid 32422940)
54. Tran J, Master Z, Yu JL, et al. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 2002;99: 4349-54. (Pubitemid 34285988)
55. Zhou J, Gan N, Zhang W, et al. Proliferation suppression and apoptosis of ovarian carcinoma cells induced by small interfering RNA against vascular endothelial growth factor. J Obstet Gynaecol Res 2010;36: 232-8.
56. Huang HY, Kuo WT, Chou MJ, Huang YY. Co-delivery of antivascular endothelial growth factor siRNA and doxorubicin by multifunctional polymeric micelle for tumor growth suppression. J Biomed Mater Res A 2011;97A: 330-338.
57. Chen Y, Bathula SR, Li J, Huang L. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J Biol Chem 2010;285: 22639-50.